NCCN Guidelines® Insights: Primary cutaneous lymphomas, version 2.2020: Featured updates to the NCCN guidelines Guidelines
| Authors: | Mehta-Shah, N.; Horwitz, S. M.; Ansell, S.; Ai, W. Z.; Barnes, J.; Barta, S. K.; Clemens, M. W.; Dogan, A.; Fisher, K.; Goodman, A. M.; Goyal, G.; Guitart, J.; Halwani, A.; Haverkos, B. M.; Hoppe, R. T.; Jacobsen, E.; Jagadeesh, D.; Lunning, M. A.; Mehta, A.; Olsen, E. A.; Pro, B.; Rajguru, S. A.; Shanbhag, S.; Shaver, A.; Shustov, A.; Sokol, L.; Torka, P.; Torres-Cabala, C.; Wilcox, R.; William, B. M.; Zain, J.; Dwyer, M. A.; Sundar, H.; Kim, Y. H. |
| Title: | NCCN Guidelines® Insights: Primary cutaneous lymphomas, version 2.2020: Featured updates to the NCCN guidelines |
| Abstract: | Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy). |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 18 |
| Issue: | 5 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2020-05-01 |
| Start Page: | 522 |
| End Page: | 536 |
| Language: | English |
| DOI: | 10.6004/jnccn.2020.0022 |
| PUBMED: | 32380458 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 June 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work